Molecular tools for assessing human depression by positron emission tomography

European Neuropsychopharmacology

Volumn 19, Issue 9, 2009, Pages 611-628

  Smith, Donald F ^a   Jakobsen, Steen ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bipolar depression; Depression; Human; Major depressive disorder; Neuroreceptor; Neurotransmission; PET brain imaging; Positron emission tomography; Unipolar depression

Indexed keywords

1,2,3,5,6,10B HEXAHYDRO 6 [4 (METHYLTHIO)PHENYL]PYRROLO[2,1 A]ISOQUINOLINE C 11; 3 (2 FLUOROETHYL)SPIPERONE F 18; 3 [3 (3 FLUOROPROPYL)THIO] 1,2,5 THIADIAZOL 4 YL 1,2,5,6 TETRAHYDRO 1 METHYLPYRIDINE F 18; 3 AMINO 4 [[2 [(DIMETHYLAMINO) METHYL]PHENYL]THIO]BENZONITRILE C 11; 4 FLUORO N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N PYRIDINYLBENZAMIDE F 18; 5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE; 5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE C 11; 6 FLUORODOPA F 18; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE C 11; ALTANSERIN F 18; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE; CITALOPRAM; DOXEPIN C 11; FLUOXETINE; FLUVOXAMINE; HARMINE C 11; ISOREMOXIPRIDE; ISOREMOXIPRIDE C 11; MCL 100907; MCNEIL 5652; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE C 11; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N 2 PYRIDINYL TRANS 4 FLUOROCYCLOHEXYLCARBOXAMIDE F 18; N METHYLTRYPTOPHAN C 11; PAROXETINE; RACLOPRIDE C 11; RADIOLIGAND; SEROTONIN UPTAKE INHIBITOR; SETOPERONE F 18; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VOLINANSERIN C 11;

BECK DEPRESSION INVENTORY; BINDING AFFINITY; BRAIN REGION; CATECHOLAMINE METABOLISM; CHOLINERGIC SYSTEM; DEPRESSION; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG UPTAKE; DRUG WITHDRAWAL; HAMILTON SCALE; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; MOLECULAR IMAGING; NEUROIMAGING; NEUROTRANSMISSION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; RECEPTOR BINDING; REVIEW; SEROTONIN METABOLISM; UNSPECIFIED SIDE EFFECT;

BRAIN; DEPRESSIVE DISORDER; DOPAMINE; HUMANS; MOLECULAR PROBES; MOLECULAR STRUCTURE; MONOAMINE OXIDASE; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, MUSCARINIC M2; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D1; RECEPTORS, HISTAMINE H1; RECEPTORS, SEROTONIN, 5-HT2; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYNAPTIC TRANSMISSION;

EID: 67650664956     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.04.005     Document Type: Review

References (72)

1. Asberg M., Thoren P., Traskman L., Bertilsson L., and Ringberger V. "Serotonin depression"-a biochemical subgroup within the affective disorders?. Science 191 (1976) 478-480
2. Beck A.T., Ward C., and Mendelson M. An inventory for measuring depression. Arch. Gen. Psychiatry 4 (1961) 571
3. Berton O., and Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 7 (2006) 137-151
4. Bhagwagar Z., Montgomery A.J., Grasby P.M., and Cowen P.J. Lack of effect of a single dose of hydrocortisone on serotonin(1A) receptors in recovered depressed patients measured by positron emission tomography with [11C]WAY-100635. Biol. Psychiatry 54 (2003) 890-895
5. Bhagwagar Z., Rabiner E.A., Sargent P.A., Grasby P.M., and Cowen P.J. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol. Psychiatry 9 (2004) 386-392
6. Bhagwagar Z., Hinz R., Taylor M., Fancy S., Cowen P., and Grasby P. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. Am. J. Psychiatry 163 (2006) 1580-1587
7. Bhagwagar Z., Murthy N., Selvaraj S., Hinz R., Taylor M., Fancy S., Grasby P., and Cowen P. 5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. Am. J. Psychiatry 164 (2007) 1858-1865
8. Boileau I., Warsh J.J., Guttman M., Saint-Cyr J.A., McCluskey T., Rusjan P., Houle S., Wilson A.A., Meyer J.H., and Kish S.J. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Mov Disord. 23 (2008) 1776-1780
9. Bragulat V., Paillere-Martinot M.L., Artiges E., Frouin V., Poline J.B., and Martinot J.L. Dopaminergic function in depressed patients with affective flattening or with impulsivity: [18F]fluoro-L-dopa positron emission tomography study with voxel-based analysis. Psychiatry Res. 154 (2007) 115-124
10. Cannon D.M., Carson R.E., Nugent A.C., Eckelman W.C., Kiesewetter D.O., Williams J., Rollis D., Drevets M., Gandhi S., Solorio G., and Drevets W.C. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch. Gen. Psychiatry 63 (2006) 741-747
11. Cannon D.M., Ichise M., Fromm S.J., Nugent A.C., Rollis D., Gandhi S.K., Klaver J.M., Charney D.S., Manji H.K., and Drevets W.C. Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol. Psychiatry 60 (2006) 207-217
12. Cannon D.M., Ichise M., Rollis D., Klaver J.M., Gandhi S.K., Charney D.S., Manji H.K., and Drevets W.C. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol. Psychiatry 62 (2007) 870-877
13. Cannon D.M., Klaver J.M., Peck S.A., Rallis-Voak D., Erickson K., and Drevets W.C. Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [(11)C]NNC-112. Neuropsychopharmacology 34 (2007) 1277-1287
14. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., and Heninger G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry 47 (1990) 411-418
15. Dougherty D.D., Bonab A.A., Ottowitz W.E., Livni E., Alpert N.M., Rauch S.L., Fava M., and Fischman A.J. Decreased striatal D1 binding as measured using PET and [11C]SCH 23,390 in patients with major depression with anger attacks. Depress. Anxiety. 23 (2006) 175-177
16. Drevets W.C., Bogers W., and Raichle M.E. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur. Neuropsychopharmacol. 12 (2002) 527-544
17. Drevets W.C., Thase M.E., Moses-Kolko E.L., Price J., Frank E., Kupfer D.J., and Mathis C. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl. Med. Biol. 34 (2007) 865-877
18. Dunlop B.W., and Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 64 (2007) 327-337
19. Fitzgerald P.B., Oxley T.J., Laird A.R., Kulkarni J., Egan G.F., and Daskalakis Z.J. An analysis of functional neuroimaging studies of dorsolateral prefrontal cortical activity in depression. Psychiatry Res. 148 (2006) 33-45
20. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg Psychiatry 12 (1960) 62
21. Hesse S., Barthel H., Schwarz J., Sabri O., and Muller U. Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. Neurosci. Biobehav. Rev. 28 (2004) 547-563
22. Hindmarch I. Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur. Psychiatry 17 Suppl 3 (2002) 294-299
23. Hirvonen J., Karlsson H., Kajander J., Lepola A., Markkula J., Rasi-Hakala H., Nagren K., Salminen J.K., and Hietala J. Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int. J. Neuropsychopharmacol. 11 (2008) 465-476
24. Ichise M., Liow J.S., Lu J.Q., Takano A., Model K., Toyama H., Suhara T., Suzuki K., Innis R.B., and Carson R.E. Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J. Cereb. Blood Flow Metab. 23 (2003) 1096-1112
25. Kano M., Fukudo S., Tashiro A., Utsumi A., Tamura D., Itoh M., Iwata R., Tashiro M., Mochizuki H., Funaki Y., Kato M., Hongo M., and Yanai K. Decreased histamine H1 receptor binding in the brain of depressed patients. Eur. J. Neurosci. 20 (2004) 803-810
26. Kasper S., Tauscher J., Willeit M., Stamenkovic M., Neumeister A., Kufferle B., Barnas C., Stastny J., Praschak-Rieder N., Pezawas L., de Zwaan M., Quiner S., Pirker W., Asenbaum S., Podreka I., and Brucke T. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder-implications for psychopharmacology. World J. Biol. Psychiatry 3 (2002) 133-146
27. Krishnan V., and Nestler E.J. The molecular neurobiology of depression. Nature 455 (2008) 894-902
28. Kuroda Y., Motohashi N., Ito H., Ito S., Takano A., Nishikawa T., and Suhara T. Effects of repetitive transcranial magnetic stimulation on [11C]raclopride binding and cognitive function in patients with depression. J. Affect. Disord. 95 (2006) 35-42
29. Lammertsma A.A. Radioligand studies: imaging and quantitative analysis. Eur. Neuropsychopharmacol. 12 (2002) 513-516
30. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb. Blood Flow Metab. 20 (2000) 423-451
31. Laruelle M., Slifstein M., and Huang Y. Positron emission tomography: imaging and quantification of neurotransporter availability. Methods 27 (2002) 287-299
32. Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., MacGregor R.R., Hitzemann R., Bendriem B., Gatley S.J., and Christman D.R. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 10 (1990) 740-747
33. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro. Endocrinol. Lett. 29 (2008) 287-291
34. Mayberg H.S. Positron emission tomography imaging in depression: a neural systems perspective. Neuroimaging Clin. N. Am. 13 (2003) 805-815
35. Meltzer H.Y., and Lowy M.T. The serotonin hypothesis of depression. In: Meltzer H.Y. (Ed). Psychopharmacology: The Third Generation of Progress (1987), Raven Press, New York 513-526
36. Meltzer C.C., Price J.C., Mathis C.A., Butters M.A., Ziolko S.K., Moses-Kolko E., Mazumdar S., Mulsant B.H., Houck P.R., Lopresti B.J., Weissfeld L.A., and Reynolds C.F. Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology 29 (2004) 2258-2265
37. Messa C., Colombo C., Moresco R.M., Gobbo C., Galli L., Lucignani G., Gilardi M.C., Rizzo G., Smeraldi E., Zanardi R., Artigas F., and Fazio F. 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology (Berl) 167 (2003) 72-78
38. Meyer J.H. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J. Psychiatry Neurosci. 32 (2007) 86-102
39. Meyer J.H., McMain S., Kennedy S.H., Korman L., Brown G.M., DaSilva J.N., Wilson A.A., Blak T., Eynan-Harvey R., Goulding V.S., Houle S., and Links P. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am. J. Psychiatry 160 (2003) 90-99
40. Meyer J.H., Houle S., Sagrati S., Carella A., Hussey D.F., Ginovart N., Goulding V., Kennedy J., and Wilson A.A. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch. Gen. Psychiatry 61 (2004) 1271-1279
41. Meyer J.H., Wilson A.A., Sagrati S., Hussey D., Carella A., Potter W.Z., Ginovart N., Spencer E.P., Cheok A., and Houle S. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am. J. Psychiatry 161 (2004) 826-835
42. Meyer J.H., Ginovart N., Boovariwala A., Sagrati S., Hussey D., Garcia A., Young T., Praschak-Rieder N., Wilson A.A., and Houle S. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry 63 (2006) 1209-1216
43. Meyer J.H., McNeely H.E., Sagrati S., Boovariwala A., Martin K., Verhoeff N.P., Wilson A.A., and Houle S. Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am. J. Psychiatry 163 (2006) 1594-1602
44. Mickey B.J., Ducci F., Hodgkinson C.A., Langenecker S.A., Goldman D., and Zubieta J.K. Monoamine oxidase A genotype predicts human serotonin 1A receptor availability in vivo. J. Neurosci. 28 (2008) 11354-11359
45. Miller J.M., Oquendo M.A., Ogden R.T., Mann J.J., and Parsey R.V. Serotonin transporter binding as a possible predictor of one-year remission in major depressive disorder. J. Psychiatr. Res. 42 (2008) 1137-1142
46. Mintun M.A., Sheline Y.I., Moerlein S.M., Vlassenko A.G., Huang Y., and Snyder A.Z. Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol. Psychiatry 55 (2004) 217-224
47. Montgomery A.J., Stokes P., Kitamura Y., and Grasby P.M. Extrastriatal D2 and striatal D2 receptors in depressive illness: pilot PET studies using [11C]FLB 457 and [11C]raclopride. J. Affect. Disord. 101 (2007) 113-122
48. Moses-Kolko E.L., Price J.C., Thase M.E., Meltzer C.C., Kupfer D.J., Mathis C.A., Bogers W.D., Berman S.R., Houck P.R., Schneider T.N., and Drevets W.C. Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635. Synapse 61 (2007) 523-530
49. Oquendo M.A., Hastings R.S., Huang Y.Y., Simpson N., Ogden R.T., Hu X.Z., Goldman D., Arango V., van Heertum R.L., Mann J.J., and Parsey R.V. Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography. Arch. Gen. Psychiatry 64 (2007) 201-208
50. Parsey R.V., Hastings R.S., Oquendo M.A., Huang Y.Y., Simpson N., Arcement J., Huang Y., Ogden R.T., van Heertum R.L., Arango V., and Mann J.J. Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am. J. Psychiatry 163 (2006) 52-58
51. Parsey R.V., Oquendo M.A., Ogden R.T., Olvet D.M., Simpson N., Huang Y.Y., van Heertum R.L., Arango V., and Mann J.J. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol. Psychiatry 59 (2006) 106-113
52. Patlak C.S., Blasberg R.G., and Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 3 (1983) 1-7
53. Praschak-Rieder N., Hussey D., Wilson A.A., Carella A., Lee M., Dunn E., Willeit M., Bagby R.M., Houle S., and Meyer J.H. Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor-treated depression: an [(18)F] MPPF positron emission tomography study. Biol. Psychiatry 56 (2004) 587-591
54. Randrup A., and Braestrup C. Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression. Psychopharmacology (Berl) 53 (1977) 309-314
55. Ravnkilde B., Videbech P., Clemmensen K., Egander A., Rasmussen N.A., Gjedde A., Rosenberg R., and Gade A. The Danish PET/depression project: cognitive function and regional cerebral blood flow. Acta Psychiatr. Scand. 108 (2003) 32-40
56. Reimold M., Batra A., Knobel A., Smolka M.N., Zimmer A., Mann K., Solbach C., Reischl G., Schwarzler F., Grunder G., Machulla H.J., Bares R., and Heinz A. Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study. Mol. Psychiatry 13 (2008) 606-613
57. Reivich M., Amsterdam J.D., Brunswick D.J., and Shiue C.Y. PET brain imaging with [11C](+)McN5652 shows increased serotonin transporter availability in major depression. J. Affect. Disord. 82 (2004) 321-327
58. Remy P., Doder M., Lees A., Turjanski N., and Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128 (2005) 1314-1322
59. Rosa-Neto P., Diksic M., Okazawa H., Leyton M., Ghadirian N., Mzengeza S., Nakai A., Debonnel G., Blier P., and Benkelfat C. Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch. Gen. Psychiatry 61 (2004) 556-563
60. Schildkraut J.J., and Kety S.S. Biogenic amines and emotion. Science 156 (1967) 21-30
61. Schildkraut J.J., Davis J.M., and Klerman G.L. Biochemistry of depressions. Psychopharmacology: A Review of Progress, 1957-1967 (1968), National Institute of Mental Health, Bethesda, Maryland 625-648
62. Sheline Y.I., Mintun M.A., Moerlein S.M., and Snyder A.Z. Greater loss of 5-HT(2A) receptors in midlife than in late life. Am. J. Psychiatry 159 (2002) 430-435
63. Sheline Y.I., Mintun M.A., Barch D.M., Wilkins C., Snyder A.Z., and Moerlein S.M. Decreased hippocampal 5-HT(2A) receptor binding in older depressed patients using [18F]altanserin positron emission tomography. Neuropsychopharmacology 29 (2004) 2235-2241
64. Smith G.S., Koppel J., and Goldberg S. Applications of neuroreceptor imaging to psychiatry research. Psychopharmacol. Bull. 37 (2003) 26-65
65. Spanagel R., and Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci. 22 (1999) 521-527
66. Stockmeier C.A. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J. Psychiatr. Res. 37 (2003) 357-373
67. Sullivan G.M., Oquendo M.A., Simpson N., van Heertum R.L., Mann J.J., and Parsey R.V. Brain serotonin1A receptor binding in major depression is related to psychic and somatic anxiety. Biol. Psychiatry 58 (2005) 947-954
68. Takikawa S., Dhawan V., Chaly T., Robeson W., Dahl R., Zanzi I., Mandel F., Spetsieris P., and Eidelberg D. Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J. Nucl. Med. 35 (1994) 955-963
69. Tanis K.Q., and Duman R.S. Intracellular signaling pathways pave roads to recovery for mood disorders. Ann. Med. (2007) 1-14
70. Theodore W.H., Hasler G., Giovacchini G., Kelley K., Reeves-Tyer P., Herscovitch P., and Drevets W. Reduced hippocampal 5HT1A PET receptor binding and depression in temporal lobe epilepsy. Epilepsia 48 (2007) 1526-1530
71. Videbech P., Ravnkilde B., Pedersen T.H., Hartvig H., Egander A., Clemmensen K., Rasmussen N.A., Andersen F., Gjedde A., and Rosenberg R. The Danish PET/depression project: clinical symptoms and cerebral blood flow. A regions-of-interest analysis. Acta Psychiatr. Scand. 106 (2002) 35-44
72. Voineskos A.N., Wilson A.A., Boovariwala A., Sagrati S., Houle S., Rusjan P., Sokolov S., Spencer E.P., Ginovart N., and Meyer J.H. Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. Psychopharmacology (Berl) 193 (2007) 539-545